Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.48 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.48 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.42 |
| ▸ | IKBKB | O14920 | 1/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 3/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | GFER | P55789 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 3/20 | 0.38 |
| ▸ | RAB9A | P51151 | 3/20 | 0.38 |
| ▸ | CASP3 | P42574 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.38 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.38 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | CA9 | Q16790 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30725401 | 0.77 | TSHR (0.37) | LMNAMEN1KMT2AGFERRAB9A | |
| SCHEMBL24309245 | 0.74 | SLC6A3 (0.40) | SLC6A3SLC6A4PTGS1IKBKBPTGS2 | |
| SCHEMBL25277220 | 0.71 | SLC6A3 (0.53) | SLC6A3SLC6A4PTGS1IKBKBPTGS2 | |
| SCHEMBL22095701 | 0.69 | SLC6A3 (0.50) | SLC6A3SLC6A4PTGS1IKBKBPTGS2 | |
| SCHEMBL12164803 | 0.68 | RAB9A (0.49) | LMNAMEN1KMT2AGFERNPC1 | |
| SCHEMBL30590680 | 0.68 | CYP46A1 (0.49) | LMNANPC1RAB9ASMN1; SMN2KDM4E | |
| SCHEMBL29111803 | 0.68 | SLC6A3 (0.52) | SLC6A3SLC6A4PTGS1MEN1KMT2A | |
| SCHEMBL6375585 | 0.67 | HTR3A (0.55) | SLC6A3SLC6A4HTR3A | |
| SCHEMBL21561527 | 0.66 | ATM (0.35) | LMNAMEN1KMT2AGFERNPC1 | |
| SCHEMBL29775120 | 0.66 | SCN4A (0.44) | SLC6A3SLC6A4LMNANPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220064170-A1 | BICYCLIC HETEROCYCLIC DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | PRELUDE THERAPUETICS INCORPORATED | 2022-03-03 | — | — | US | disclosed |
| US-20220064170-A1 | BICYCLIC HETEROCYCLIC DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | PRELUDE THERAPUETICS INCORPORATED | 2022-03-03 | — | — | US | disclosed |
| WO-2020123994-A1 | 2-((5-(PHENYL)-PYRROLO[2,1-F][1,2,4]TRIAZIN-4-YL)AMINO)-3-(PHENYL)PROPANOIC ACID DERIVATIVES AND RELATED COMPOUNDS AS MCL-1 ENZYME INHIBITORS FOR TREATING CANCER | PRELUDE THERAPEUTICS, INCORPORATED (US) | 2020-06-18 | — | — | WO | disclosed |
| WO-2020123994-A1 | 2-((5-(PHENYL)-PYRROLO[2,1-F][1,2,4]TRIAZIN-4-YL)AMINO)-3-(PHENYL)PROPANOIC ACID DERIVATIVES AND RELATED COMPOUNDS AS MCL-1 ENZYME INHIBITORS FOR TREATING CANCER | PRELUDE THERAPEUTICS, INCORPORATED (US) | 2020-06-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220064170-A1 | BICYCLIC HETEROCYCLIC DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | CYP2C19, CYP2D6, CYP2C8 | SLC6A3 2811/4885SLC6A4 2508/4885PTGS1 1336/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.